Change in Aberrant Behavior Checklist - Social Withdrawal (ABC-SW) Subscale - Study 1
| Group | Value (score on a scale) | Spread |
|---|---|---|
| Study 1: Insulin-Like Growth Factor-1 (IGF-1) | 15.78 | 9.16 |
| Study 1: Normal Saline | 11.22 | 7.29 |
Trial · Interventional
CompletedPhase 2Results postedRegistry dataUnited States
1 trial · 1 completed · 1 with posted results
Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)
NCT01525901Feb 2012 to 23 Aug 2016
Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.
The purpose of this study is to pilot the use of Insulin-Like Growth Factor-1 (IGF-1) treatment in 22q13 Deletion Syndrome (Phelan-McDermid Syndrome) caused by SHANK3 gene deficiency in order to evaluate safety, tolerability, and efficacy. IGF-1 is an injection under the skin that contains human IGF-1. IGF-1 is approved by the FDA under the brand name Increlex for the treatment of children with short stature due to primary IGF-1 deficiency. It is being used off-label in the current study and is not FDA approved, nor has it yet been studied in humans for the treatment of SHANK3 deficiency.
Experimental
Insulin-Like Growth Factor-1 (IGF-1)
Injection
Placebo comparator
Normal saline
Injection
Outcomes the sponsor listed as primary.
Change in Aberrant Behavior Checklist - Social Withdrawal (ABC-SW) Subscale - Study 1
Time frame · Baseline and Week 12
16 items on ABC-SW subscale, Each item is scored as 0 (never a problem), 1 (slight problem), 2 (moderately serious problem), or 3 (severe problem). Total score from 0 to 48 with higher score indicating poorer health outcomes.
Change in Aberrant Behavior Checklist - Social Withdrawal (ABC-SW) Subscale Study 2
Time frame · Baseline and Week 12
16 items on ABC-SW subscale, Each item is scored as 0 (never a problem), 1 (slight problem), 2 (moderately serious problem), or 3 (severe problem). Total score from 0 to 48 with higher score indicating poorer health outcomes..
Change in Repetitive Behavior Scale - Study 2
Time frame · Baseline and Week 12
Repetitive Behavior Scale (RBS) - Total Score 43 items, each item scored on 4-point scale: 0-Behavior does not occur, 1-Behavior occurs and is a mild problem, 2-Behavior occurs and is a moderate problem, 3-Behavior occurs and is a severe problem. with total score from 0 (mild) to 129 (severe). The subscales are stereotyped behaviors 6 items (subscale 0-18), self-injurious behaviors 8 items (subscale 0-24), Compulsive behaviors- 8 items (subscale 0-24), Ritualistic Behaviors 6 items (subscale from 0-18), Sameness 11 items (subscale 0-33), restricted behaviors 4 items (subscale 0-12). Total score is the sum of all items in the subscale with total score range from 0 to 129. Higher scores indicate greater symptom severity.
Change in CGI-Improvement and Severity Scales; - Study 2
Time frame · Baseline and Week 12
The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. The Clinical Global Impression - Improvement scale (CGI-I) is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. and rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.
Change in Caregiver Strain Questionnaire
Time frame · Baseline and Week 12
21 question tool, about caregiver strain, where each question uses a Likert scale where 1 is "Not at all" and 5 is "Very much." The full scale ranges from 21-105, where higher scores indicate more severe strain.
Change in Sensory Profile (SP) - Study 2
Time frame · Baseline and Week 12
The SP is a standardized parent-completed questionnaire that assesses sensory processing and its impact on the functioning of children ages 3-10 yr. The 125 items represent behaviors that can be interpreted as responses to sensory experiences. The parent rates the observed frequency of these behaviors on a 5-point Likert scale (ranging from 1 always to 5 never). The tool consists of 14 sections, listed below, that refer to sensory processing, modulation, and behavioral and emotional responses. Subscale scores are listed below. Each section's raw score is compared with a threshold value to determine a category of performance: typical performance, probable difference (1 standard deviation below the mean), and definite difference (2 standard deviations below the mean). A lower raw score means a greater difference.
Change in Short Sensory Profile (SSP) - Study 2
Time frame · Baseline and 12 weeks
The Short Sensory Profile is a caregiver report measure consisting of 38 items, each scored on a 1-point (always) to 5-point (never) Likert scale. SSP Subscales Tactile Sensitivity (7 to 35) Taste/Smell Sensitivity (4 to 20), Movement Sensitivity (3 to 15), Under-Responsive/Seek Sensation (7 to 35) , Auditory Filtering (6 to 30), Low Energy/Weak (6 to 30), Visual/Auditory Sensitivity (5 to 25), with total scale from (38 to 190) Lower scores indicate more sensory alterations.
Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.
| Group | Value (score on a scale) | Spread |
|---|---|---|
| Study 1: Insulin-Like Growth Factor-1 (IGF-1) | 15.78 | 9.16 |
| Study 1: Normal Saline | 11.22 | 7.29 |
| Group | Value (score on a scale) | Spread |
|---|---|---|
| Study 2: IGF-1 | -5.5 | 7.46 |
| Study 2: Placebo | -6.3 | 5.38 |
| Group | Value (score on a scale) | Spread |
|---|---|---|
| Study 2: IGF-1 | -0.3 | 2.63 |
| Study 2: Placebo | -0.8 | 2.19 |
| Group | Value (score on a scale) | Spread |
|---|---|---|
| Study 2: IGF-1 | -0.2 | 0.42 |
| Study 2: Placebo | -0.1 | 0.32 |
| Group | Value (score on a scale) | Spread |
|---|---|---|
| Study 1: Insulin-Like Growth Factor-1 (IGF-1) | 64.11 | 17.32 |
| Study 1: Normal Saline | 63.22 | 20.48 |
| Study 2: Insulin-Like Growth | 58 | 18.89 |
| Study 2: Normal Saline | 55.00 | 19.54 |
| Group | Value (units on a scale) | Spread |
|---|---|---|
| Study 2: IGF-1 | 1.6 | 2.46 |
| Study 2: Placebo | 0.2 | 2.39 |
| Group | Value (score on a scale) | Spread |
|---|---|---|
| Study 2: IGF-1 | 0.9 | 2.73 |
| Study 2: Placebo | 0.7 | 2.45 |
| Group | Deaths | Serious events | Other events |
|---|---|---|---|
| Insulin-Like Growth Factor-1 (IGF-1)IGF-1 is an aqueous solution for injection containing human insulin-like growth factor-1 (Increlex; Ipsen Biopharmaceuticals, Inc)) produced by recombinant DNA technology. Dose titration was initiated at 0.04 mg/kg twice daily by subcutaneous injection, and increased, as tolerated, every week by 0.04 mg/kg per dose to a maximum of 0.12 mg/kg twice daily. Medication was administered subcutaneously twice daily with meals and glucose monitoring was performed by parents prior to each injection and at bedtime. | 0 / 19 | 0 / 19 | 19 / 19 |
| Normal SalinePlacebo | 0 / 19 | 0 / 19 | 19 / 19 |
Each cell reads participants affected / participants at risk, as the registry posted them.
Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works
Studies that cite this trial.
No study cites this trial.
References listed at the registry that are not in PepBank. They link to PubMed.
Who could join, as posted.
PepBank is a research reference. Talk to a doctor before you use any peptide.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated